版本:
中国

BRIEF-Arqule initiates early-stage trial of ARQ 092

June 7 Arqule Inc

* Arqule announces first patient dosed in company sponsored phase 1/2 trial of akt inhibitor, ARQ 092, for rare overgrowth diseases

* Phase 1/2 trial with co's akt inhibitor, arq 092, will enroll patients with overgrowth diseases driven by pi3k/akt1 pathway Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐